Exelixis and Bristol-Myers collaboration extended
The collaboration, which was originally established for a period of two years, has been extended at Bristol-Myers Squibb’s request. Under the terms of the collaboration, the two companies
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.